• (2nd September, 2014; Business Wire India); Five years on from the first breakthrough presentation of the pivotal RE-LY® clinical trial of Pradaxa® (dabigatran etexilate) for the prevention of stroke in non-valvular atrial fibrillation (NVAF), extensive clinical trial and real-world data support Pradaxa® in various indications. Boehringer Ingelheim continues to grow the evidence base for Pradaxa® to improve care for patients at risk of blood clots and today announces the initiation of Phase III of the GLORIA™-AF registry program in North America and in Europe. During this final phase of the registry program, data on the overall safety and effectiveness of antithrombotic treatments will be collected.

  • (22nd August, 2014; Business Wire India); Celgene Corporation (NASDAQ:CELG) announced that results of a study evaluating the combination of REVLIMID® (lenalidomide) with rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and prednisone (R-CHOP) in untreated diffuse large b-cell lymphoma (DLBCL) were published online ahead of print in the Journal of Clinical Oncology.

  • (29th July, 2014); Looking at the current regulatory environment of clinical trial in India, it is important that all information related to 4 major domains i.e, Sponsor/ CRO, Investigator, Ethics Committee, Patient of clinical trials are captured through online in an organized manner. Hence, for ensuring transparency and faster dissemination of information about clinical trials, health ministry may start information technology (IT) enabled platform. The recommendation of such platform is provided by Prof. Ranjit Roy Chaudhary Committee.

  • 20 June 2014
    Type 2 Diabetes: Jardiance® (empagliflozin) as an add-on therapy significantly reduced blood glucose and body weight in two newly presented Phase III trials

    (20th June, 2014); Boehringer Ingelheim and Eli Lilly and Company presented results of two Phase III clinical trials studying the efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in adults with Type 2 Diabetes (T2D) at the American Diabetes Association's 74th Scientific Sessions®. Results showed that empagliflozin in combination with certain other diabetes therapies reduced blood glucose, body weight and blood pressure.

  • (Business Wire India; 5th June, 2014); Kinetic Concepts, Inc. announced today that a new study, published in the International Wound Journal, showed the Prevena™ Incision Management System used over closed incisions for the first six to seven days reported a significantly lower infection rate than conventional dressings in patients undergoing cardiac surgery via median sternotomy. Post-sternotomy wound infection is a serious, potentially fatal complication of cardiac surgery which often requires additional surgery, and is associated with significantly increased health care costs.

  • 8 January 2011
    Ecron Acunova CRO and Chulalongkorn University’s arm form Joint venture for clinical research

    Ecron Acunova (EA), a leading CRO with presence in Europe and Asia announced a joint venture with Jamjuree Innovations Co. Ltd., (JJI) Thailand. JJI is a 100% subsidiary of Chulalongkorn University Intellectual Property Foundation and enjoys strong ties with the University’s Faculty of Medicine, including Clinical Research Center (Chula CRC). The joint venture CRO is based in Bangkok and will conduct clinical research in key South East Asian countries under the name Ecron Acunova Company Ltd (EACL). Dr.

  • 6 July 2010
    NEWS: Intercell vaccine patch fails Phase II clinical trial

    Intercell's investigational vaccine enhancement patch system for avian H5N1 influenza has failed a Phase II study. The company is working under a contract with Human and Health services (HHS) to develop a dose-sparing approach with potential for a single dose immunization combining a H5N1 vaccine with Intercell's LT adjuvant patch.

    [adsense:336x280:8701650588]

Subscribe to CR News